Extensively drug resistant tuberculosis in a high income country: A report of four unrelated cases

BMC Infectious Diseases

Volumn 8, Issue , 2008, Pages

  Blaas, Stefan H ^a,b   Mütterlein, Ralf ^c   Weig, Johannes ^d   Neher, Albert ^e   Salzberger, Bernd ^a   Lehn, Norbert ^a   Naumann, Ludmila ^f  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Donaustauf Hospital   (Germany)

^c District Hospital   (Germany)

^d Public Health Department   (Germany)

^e ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^f BAVARIAN HEALTH AND FOOD SAFETY AUTHORITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLOFAZIMINE; CYCLOSERINE; DOXYCYCLINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CASE REPORT; DEATH; DIRECTLY OBSERVED THERAPY; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; GERMANY; HEALTH CARE COST; HEALTH CARE FACILITY; HOSPITAL CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; INCOME; INDUSTRIALIZATION; INFECTION CONTROL; LUNG LOBECTOMY; LUNG RESECTION; LUNG TUBERCULOSIS; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM AFRICANUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM MICROTI; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT COMPLIANCE; PUBLIC HEALTH PROBLEM; QUALITY OF LIFE; RUSSIAN FEDERATION; SOUTH AFRICA; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; YUGOSLAVIA; DRUG EFFECT; ETHNOLOGY; GEORGIA (REPUBLIC); MICROBIOLOGY; MIDDLE AGED; MIGRATION; SOCIAL CLASS; SPUTUM;

ADULT; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; EMIGRATION AND IMMIGRATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GEORGIA (REPUBLIC); GERMANY; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RUSSIA; SOCIAL CLASS; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS; YUGOSLAVIA;

EID: 44949239509     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-8-60     Document Type: Article

References (17)

1. Olle-Goig JE Editorial: The treatment of multi-drug resistant tuberculosis - a return to the pre-antibiotic era? Trop Med Int Health 2006, 11:1625-1628. 10.1111/j.1365-3156.2006.01770.x 17054741
2. Raviglione M XDR-TB: Entering the post-antibiotic era? Int J Tuberc Lung Dis 2006, 10:1185-1187. 17131774
3. Centers for Disease Control and Prevention Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004 MMWR Morb Mortal Wkly Rep 2006, 55:301-305. 16557213
4. Gandhi NR Moll A Sturm AW Pawinski R Govender T Lalloo U Zeller K Andrews J Friedland G Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa Lancet 2006, 368:1575-1580. 10.1016/ S0140-6736(06)69573-1 17084757
5. Organization WH Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control Wkly Epidemiol Rec 2006, 81:430-432. 17096498
6. Organization WH Guidelines for the programmatic management of drug-resistant tuberculosis Geneva, Switzerland; 2006.
7. Laserson KF Thorpe LE Leimane V Weyer K Mitnick CD Riekstina V Zarovska E Rich ML Fraser HS Alarcon E Cegielski JP Grzemska M Gupta R Espinal M Speaking the same language: Treatment outcome definitions for multidrug-resistant tuberculosis Int J Tuberc Lung Dis 2005, 9:640-645. 15971391
8. Brodhun B Altmann D Haas W Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2005 Berlin, Robert Koch-Institut; 2007.
9. Haas W Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2001 Berlin, Robert Koch-Institut; 2003.
10. Adjers-Koskela K Katila ML Susceptibility testing with the manual mycobacteria growth indicator tube (MGIT) and the MGIT 960 system provides rapid and reliable verification of multidrug-resistant tuberculosis J Clin Microbiol 2003, 41:1235-1239. 150305 12624056 10.1128/JCM.41.3.1235-1239.2003
11. Cullen MM Sam NE Kanduma EG McHugh TD Gillespie SH Direct detection of heteroresistance in Mycobacterium tuberculosis using molecular techniques J Med Microbiol 2006, 55:1157-1158. 10.1099/jmm.0.46483-0 16849739
12. Heep M Brandstatter B Rieger U Lehn N Richter E Rusch-Gerdes S Niemann S Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates J Clin Microbiol 2001, 39:107-110. 87688 11136757 10.1128/JCM.39.1.107-110.2001
13. Karahan ZC Akar N Restriction endonuclease analysis as a solution for determining rifampin resistance mutations by automated DNA sequencing in heteroresistant Mycobacterium tuberculosis strains Microb Drug Resist 2005, 11:137-140. 10.1089/mdr.2005.11.137 15910227
14. Rinder H Mieskes KT Loscher T Heteroresistance in Mycobacterium tuberculosis Int J Tuberc Lung Dis 2001, 5:339-345. 11334252
15. Van Rie A Victor TC Richardson M Johnson R van der Spuy GD Murray EJ Beyers N Gey van Pittius NC van Helden PD Warren RM Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns Am J Respir Crit Care Med 2005, 172:636-642. 10.1164/rccm.200503-449OC 15947286
16. Deutsche Zentralkomitee zur Bekämpfung der Tuberkulose Empfehlungen zur Infektionsverhütung bei Tuberkulose Frankfurt am Main, pMI Verlagsgruppe GmbH; 1996.
17. Parmet WE Legal power and legal rights - isolation and quarantine in the case of drug-resistant tuberculosis N Engl J Med 2007, 357:433-435. 10.1056/NEJMp078133 17671251